Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Data on antimicrobial resistance patterns and respective MIC90 of isolated bacteria.

From: Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital

  2002 2003 2004 2005
Microorganisms S* I** R*** MIC90 # S I R MIC90 S I R MIC90 S I R MIC90
Gram-positive                 
Staphylococcus epidermidis                 
Oxacillin 31/202 0/202 171/202 4 46/261 0/261 215/261 4 36/214 0/214 179/214 4 15/94 0/94 75/94 4
Gentamicin 58/202 18/202 126/202 16 87/261 20/261 154/261 16 71/219 0/219 148/219 16 40/94 10/94 44/94 16
Vancomycin 202/202 0/202 0/202 2 261/261 0/261 0/261 2 219/219 0/219 0/219 2 94/94 0/94 0/94 4
Staphylococcus aureus                 
Oxacillin 13/38 0/38 25/38 4 9/30 0/30 21/30 4 13/25 0/25 12/25 4 2/8 0/8 6/8 4
Gentamicin 16/38 13/38 9/38 8 21/30 5/30 4/30 8 19/25 0/25 6/25 4 5/8 1/8 2/8 0.5
Vancomycin 38/38 0/38 0/38 1 30/30 0/30 0/30 2 25/25 0/25 0/25 1 8/8 0/8 0/8 1
Enterococcus faecalis                 
Vancomycin 14/14 0/14 0/14 2 17/19 0/19 2/19 2 6/6 0/6 0/6 2 4/4 0/4 0/4 2
Enterococcus faecium                 
Vancomycin 13/14 0/14 1/14 1 8/8 0/8 0/8 1 2/2 0/2 0/2 32 2/2 0/2 0/2 1
Gram negative                 
Acinetobacter baumannii                 
Amikacin 3/9 1/9 5/9 64 5/15 0/15 10/15 64 3/35 2/35 30/35 64 2/17 2/17 13/17 64
Ceftazidime 1/9 2/9 6/9 64 2/15 1/15 12/15 64 1/35 0/35 34/35 64 0/17 0/17 17/17 64
Ciprofloxacin 3/9 0/9 6/9 4 3/15 0/15 12/15 4 1/35 0/35 34/35 4 0/17 0/17 17/17 4
Colistin 8/9 0/9 1/9 2 15/15 0/15 0/15 1 35/35 0/35 0/35 2 16/17 0/17 1/17 0.5
Gentamicin 5/9 0/9 4/9 16 5/15 5/15 5/15 16 19/35 6/35 10/35 16 5/17 4/17 8/17 16
Imipenem 5/9 2/9 2/9 16 6/15 4/15 5/15 16 1/35 5/35 29/35 16 0/17 4/17 13/17 16
Piperacillin/Tazobactam 2/9 1/9 6/9 128 4/15 1/15 10/15 128 1/35 1/35 33/35 128 0/17 3/17 14/17 128
Pseudomonas aeruginosa                 
Amikacin 15/29 2/29 12/29 64 18/33 1/33 14/33 64 8/25 0/25 17/25 64 7/11 0/11 4/11 64
Ceftazidime 13/29 2/29 15/29 64 14/33 5/33 14/33 64 4/25 7/25 14/25 64 3/11 1/11 7/11 64
Ciprofloxacin 11/29 0/29 18/29 4 14/33 0/33 19/33 4 8/25 0/25 17/25 4 6/11 0/11 5/11 4
Colistin 29/29 0/29 0/29 2 33/33 0/33 0/33 2 25/25 0/25 0/25 2 11/11 0/11 0/11 2
Imipenem 11/29 14/29 4/29 16 19/33 9/33 5/33 16 10/25 6/25 9/25 16 6/11 4/11 1/11 16
Piperacillin/Tazobactam 26/29 0/29 3/29 64 26/33 1/33 6/33 128 7/25 11/25 7/25 128 9/11 0/11 2/11 128
Klebsiella pneumoniae                 
Ceftazidime 5/7 0/7 2/7 64 23/34 0/34 11/34 64 14/29 1/29 14/29 64 2/11 0/11 9/11 64
Ciprofloxacin 6/7 0/7 1/7 1 22/34 1/34 11/34 4 13/29 0/29 16/29 4 7/11 0/11 4/11 4
Meropenem 7/7 0/7 0/7 0.25 33/34 0/34 1/34 0.5 21/29 4/29 4/29 8 2/11 1/11 8/11 16
Cefepime 7/7 0/7 0/7 2 23/34 1/34 10/34 64 14/29 7/29 8/29 64 2/11 0/11 9/11 64
Cefoxitin 7/7 0/7 0/7 4 24/34 0/34 10/34 64 11/29 0/29 18/29 64 2/11 0/11 9/11 64
Tobramycin 7/7 0/7 0/7 1 26/34 0/34 8/34 16 12/29 1/29 16/29 16 2/11 2/11 7/11 16
Piperacillin/Tazobactam 7/7 0/7 0/7 8 26/34 1/34 7/34 128 14/29 2/29 13/29 128 2/11 0/11 9/11 128
Escherichia coli                 
Amikacin 35/35 0/35 0/35 2 57/57 0/57 0/57 2 43/47 4/47 0/47 4 29/30 0/30 1/30 4
Ciprofloxacin 28/35 0/35 7/35 4 54/57 0/57 3/57 0.5 43/47 0/47 4/47 4 21/30 0/30 9/30 4
Piperacillin/Tazobactam 34/35 0/35 1/35 4 56/57 1/57 0/57 4 43/47 1/47 3/47 8 28/30 1/30 1/30 4
Ceftazidime 33/35 0/35 2/35 2 57/57 0/57 0/57 1 43/47 3/47 1/47 1 25/30 0/30 5/30 2
Cefoxitin 31/35 1/35 3/35 16 56/57 1/57 0/57 4 43/47 4/47 0/47 4 26/30 1/30 3/30 16
Meropenem 34/35 1/35 0/35 0.25 57/57 0/57 0/57 0.25 46/47 0/47 1/47 0.25 30/30 0/30 0/30 2
  1. Abbreviations: *S = susceptible, **I = intermediate, ***R = resistant, # MIC 90 = minimum inhibitory concentration for 90% of the corresponding microbial population